Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- 4BB.LSE
- Price
- 1120.00
- Stock movement up
- +- (%)
- Company name
- 4BASEBIO UK SOCIETAS
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Biotechnology
- Market cap
- 17.33B
- Ent value
- 17.35B
- Price/Sales
- 22808.80
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 14.87%
- 3 year return
- 29.98%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-03-21
DIVIDENDS
4BB.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 22808.80 |
| Price to Book | - |
| EV to Sales | 22827.78 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 15.48M |
| EPS (TTM) | -0.77 |
| FCF per share (TTM) | -0.73 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 760.00K |
| Gross profit (TTM) | 579.00K |
| Operating income (TTM) | -10.14M |
| Net income (TTM) | -9.84M |
| EPS (TTM) | -0.77 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 76.18% |
| Operating margin (TTM) | -1334.74% |
| Profit margin (TTM) | -1294.47% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.72M |
| Net receivables | 52.00K |
| Total current assets | 4.92M |
| Goodwill | 2.16M |
| Intangible assets | 816.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 11.93M |
| Accounts payable | 795.00K |
| Short/Current long term debt | 15.49M |
| Total current liabilities | 1.80M |
| Total liabilities | 17.15M |
| Shareholder's equity | -5.22M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -8.33M |
| Capital expenditures (TTM) | 653.00K |
| Free cash flow (TTM) | -9.31M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -82.48% |
| Return on Invested Capital | 196.84% |
| Cash Return on Invested Capital | 186.37% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1120.00 |
| Daily high | 1132.00 |
| Daily low | 1091.00 |
| Daily Volume | 0K |
| All-time high | 1820.00 |
| 1y analyst estimate | 1800.00 |
| Beta | 1.13 |
| EPS (TTM) | -0.77 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| 4BB.LSE | S&P500 | |
| Current price drop from All-time high | -38.46% | -7.74% |
| Highest price drop | -47.71% | -56.47% |
| Date of highest drop | 13 Jul 2022 | 9 Mar 2009 |
| Avg drop from high | -19.31% | -11.07% |
| Avg time to new high | 20 days | 12 days |
| Max time to new high | 606 days | 1805 days |
COMPANY DETAILS
Marketcap
17.33B
Marketcap category
Large-cap
Description
4basebio PLC engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company offers AVV and Lentivirus manufacturing services for use in gene therapies and vaccines. It also offers access to its targeted non-viral delivery platform, Hermes. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is based in Cambridge, the United Kingdom.
Employees
101
Website
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found